KNSA · Kiniksa Pharmaceuticals International, plc
$78.47
-2.33 (-2.88%)
At close · Aug 20
Market Cap
$12.61B
Shares
156.05M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$78.47
Open$79.43
Day$77.64–80.12
52W close$33.04–80.92
Avg vol 30d639K
Short int4.3M · 2.8% float · 5.0d
Short vol35%
Last earningsJul 28, 2026
DataJan 2020–Aug 2026
Filing10-Q · Jul 28
Up next
Next earnings call
Oct 27, 2026
Est · unconfirmed
· in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Jul 28, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+55%
above
Price vs 50-day avg
+18%
above
RSI (14)
62
neutral
MACD trend
Negative
52-week position
95%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+24%
trailing
6-month return
+76%
trailing
YTD return
+90%
this year
Relative strength
+65%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $66 › 200d $51 — 50d above 200d
Institutional flow
Accumulating
+16% holders QoQ · +71 funds added
Insider flow
Distributing
Net -$299.1K over 90 days · 100% sells
Short interest
Falling
2.77% of float · ▼ -4.3% MoM · 5.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
266 holders — near 2-yr high, broad support
Squeeze score
57
elevated · 0–100
Fundamentals
Revenue growth
+60%
Y/Y
EPS growth
+225%
Y/Y
Free cash flow
$136.4M
Valuation
P/E 88.8
rich
Balance sheet
$165.6M
net cash
Quant / Vol
risk profile
Volatility
50%
annualized · 1-yr
Max drawdown
−21%
past year
ATR
3.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Jun 30, 2026
Full year 2026 revenue
· full year 2026
$980M – $995M
Prior guidance
period ended
· from the Earnings Call filed Sep 30, 2025
ARCALYST net sales
· full year 2025
$670M – $675M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+55%
Bullish
Price vs 50-day avg
+18%
Bullish
RSI (14)
62
Neutral
MACD trend
Negative
Bearish
52-week position
95%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $66 › 200d $51 — 50d above 200d
Institutional flow
Accumulating
+16% holders QoQ · +71 funds added
Insider flow
Distributing
Net -$299.1K over 90 days · 100% sells
Short interest
Falling
2.77% of float · ▼ -4.3% MoM · 5.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
266 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $33
Now $78 · 95%
Range high $81
vs 200-day avg +55%
vs 50-day avg +18%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| ARCALYST net product revenue | $243.6M | the second quarter of 2026 | +55.4% |
|
|
|||
| Average total duration of ARCALYST therapy in recurrent pericarditis | 3 | the second quarter of 2026 | — |
| Multiple-recurrence patients actively on ARCALYST treatment | 21% | the second quarter of 2026 | — |
|
|
|||
| Number of multiple-recurrence patients | 14,000 | the second quarter of 2026 | — |
|
|
|||
| Prescribers who have written ARCALYST prescriptions for recurrent pericarditis since launch | 5,000 | the second quarter of 2026 | — |
| Cash balance increase in 2025 | $170.4M | the full year 2025 | — |
| Gross-to-net | 8.4% | the full year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KNSA
this stock
Kiniksa Pharmaceuticals International, plc
|
$12.61B | +90.2% | +60.1% | 88.8 | 2.8% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$64.91B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$57.85B | +16.3% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$50.24B | +1.7% | — | — | 0.0% |
|
HLN
Haleon plc
|
$43.41B | -2.4% | — | — | 0.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KNSA | +0.8% | +24.5% | +76.4% | +5.6% | +90.2% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +2.8% | +21.2% | +65.2% | +3.5% | +78.4% |
Key facts
CIK
1730430
CUSIP
G52694109
13F (30d)
247 filings
246 filers
Visit website
Investor relations